The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourNOUVEAU
31 août 2026
31 août 2026
13%
31 décembre 2026
51%
$2,649 Vol.
31 août 2026
$943 Vol.
13%
31 décembre 2026
$1,706 Vol.
51%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Marché ouvert : Jun 22, 2026, 10:10 PM ET
Volume
$2,649Date de fin
31 déc. 2026Marché ouvert
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,649Date de fin
31 déc. 2026Marché ouvert
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes